Trials / Terminated
TerminatedNCT03381833
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
A Multi-Center, Randomized, Open-Label, Parallel-Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- La Jolla Pharmaceutical Company · Industry
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase 2 multicenter, randomized, open-label, parallel-group study. The primary objective of the study is to evaluate the effect of LJPC-401 (synthetic human hepcidin) on iron levels in patients with transfusion-dependent beta thalassemia with myocardial iron overload.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LJPC-401 | subcutaneous injection, up to 20 mg per week from week 26 to 52 |
| DRUG | LJPC-401 | subcutaneous injection, up to 20 mg per week from week 1 to 52 |
Timeline
- Start date
- 2017-11-30
- Primary completion
- 2019-12-03
- Completion
- 2020-01-14
- First posted
- 2017-12-22
- Last updated
- 2021-07-29
Locations
22 sites across 8 countries: United States, Australia, Greece, Italy, Lebanon, Thailand, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03381833. Inclusion in this directory is not an endorsement.